Editorial Videos

Yerem Yeghiazarians, MD, discusses the importance of understanding why certain cells (like cancer cells) can survive in situations that would kill other healthy cells.

For pharma products, ensuring proper delivery requires the majority of work to occur before the product hits the road.

While the space has traditionally been dominated by smaller biotechs, that may be changing.

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur.

Ankit Jain, CEO, Co-Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions.

Pharma products face unique issues related to chain-of-custody and cold chain.

Ankit Jain, CEO, Co-Founder, Infinitus touches on the approach to human oversight in an effort to build trust in autonomous patient access workflows by keeping humans and AI in a continuous feedback loop.

Ankit Jain, CEO, Co-Founder, Infinitus, discusses how AI-native patient access infrastructure appears to be less about replacing care teams and more about eliminating the friction between diagnosis and therapy initiation.

Matthew Turner, President of Patient Affordability, Paysign, discusses Paysign's approach to measuring copay program value in an effort to move beyond simple redemption counts toward a more complete picture of patient adherence.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

While digital clinical trials provide more opportunity, they also present unique challenges that can significantly impact the trial results.

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing manufacturers toward more sophisticated, partnership-driven program designs.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, mentions how eClinical Solutions positioned its elluminate platform as part of an effort to help sponsors meet heightened evidence and oversight demands.

New technologies are impacting the speed-to-therapy within hub services.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical development appearing to be part of a broader effort to strengthen trial evidence.

Vivalink’s CEO Jiang Li, PhD, discusses the importance of including as much information with clinical data as possible.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering the scientific bar.

Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.

In the second part of his conversation with Pharmaceutical Executive, Ajna Biosciences CEO Joel Stanley explains the complexities of getting a botanical drug approved.

In this Pharmaceutical Executive Academy discussion, Najat Khan, PhD, CEO of Recursion Pharmaceuticals and former chief data science officer at J&J, explores the intersection of AI, pharma, and patient care — and the strategic pivots necessary to drive measurable and lasting gains across the value chain.

Ajna Biosciences CEO Joel Stanley discusses the differences between botanical drugs and botanically-derived drugs.

Joseph Kleiman examines how Trump Rx could pressure pharmacy benefit managers and retailers to increase transparency and affordability, while cautioning that its long-term impact will depend on price consistency.

In the final part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses the challenges that pharma faces when marketing direct-to-consumers.

Buzz Health President Joseph Kleiman discusses how TrumpRx is reshaping drug price transparency, highlighting the benefits of early price visibility for consumers alongside the operational challenges of fluctuating costs, consistency and potential.

Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects.